Subscribe
29 October 2013Asia

Bayer’s compulsory licence appeal set to start in India

A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Bayer takes another swipe at Nexavar compulsory licence
15 October 2013   Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Asia
Bayer takes another swipe at Nexavar compulsory licence
15 October 2013   Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

More on this story

Asia
Bayer takes another swipe at Nexavar compulsory licence
15 October 2013   Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility